Logo image of ATNM

ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:ATNM - US00507W2061 - Common Stock

1.34 USD
+0.02 (+1.52%)
Last: 1/22/2026, 8:23:11 PM
1.35 USD
+0.01 (+0.75%)
After Hours: 1/22/2026, 8:23:11 PM
Fundamental Rating

2

Taking everything into account, ATNM scores 2 out of 10 in our fundamental rating. ATNM was compared to 525 industry peers in the Biotechnology industry. The financial health of ATNM is average, but there are quite some concerns on its profitability. ATNM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ATNM has reported negative net income.
  • ATNM had a negative operating cash flow in the past year.
  • In the past 5 years ATNM always reported negative net income.
  • In the past 5 years ATNM reported 4 times negative operating cash flow.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

  • ATNM's Return On Assets of -65.12% is on the low side compared to the rest of the industry. ATNM is outperformed by 60.38% of its industry peers.
  • The Return On Equity of ATNM (-215.83%) is worse than 69.33% of its industry peers.
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

  • ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ATNM has more shares outstanding
  • ATNM has more shares outstanding than it did 5 years ago.
  • ATNM has a better debt/assets ratio than last year.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • ATNM has an Altman-Z score of -9.61. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
  • ATNM has a Altman-Z score of -9.61. This is in the lower half of the industry: ATNM underperforms 71.05% of its industry peers.
  • ATNM has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.00, ATNM is in line with its industry, outperforming 52.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.61
ROIC/WACCN/A
WACC8.9%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • ATNM has a Current Ratio of 7.34. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 7.34, ATNM is in the better half of the industry, outperforming 71.62% of the companies in the same industry.
  • A Quick Ratio of 7.34 indicates that ATNM has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 7.34, ATNM is in the better half of the industry, outperforming 71.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.34
Quick Ratio 7.34
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.43% over the past year.
  • ATNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ATNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.82% yearly.
  • ATNM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 265.08% yearly.
EPS Next Y13.26%
EPS Next 2Y16.17%
EPS Next 3Y13.56%
EPS Next 5Y14.82%
Revenue Next Year-76.23%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y265.08%

3.3 Evolution

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATNM. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • ATNM's earnings are expected to grow with 13.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.17%
EPS Next 3Y13.56%

More info and screens

0

5. Dividend

5.1 Amount

  • ATNM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (1/22/2026, 8:23:11 PM)

After market: 1.35 +0.01 (+0.75%)

1.34

+0.02 (+1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners19.79%
Inst Owner Change0%
Ins Owners2.36%
Ins Owner Change-1.12%
Market Cap41.81M
Revenue(TTM)N/A
Net Income(TTM)-41.04M
Analysts81.82
Price Target5.1 (280.6%)
Short Float %2.87%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.9%
Min EPS beat(2)-80.18%
Max EPS beat(2)38.38%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-80.18%
Max EPS beat(4)44.95%
EPS beat(8)6
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)2.81%
EPS beat(16)8
Avg EPS beat(16)-7.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.42%
EPS NY rev (1m)0%
EPS NY rev (3m)19.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.2
P/tB 2.2
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.34
Quick Ratio 7.34
Altman-Z -9.61
F-Score2
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)25.77%
Cap/Depr(5y)31.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
EPS Next Y13.26%
EPS Next 2Y16.17%
EPS Next 3Y13.56%
EPS Next 5Y14.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-76.23%
Revenue Next 2Y-41.42%
Revenue Next 3Y526.75%
Revenue Next 5Y265.08%
EBIT growth 1Y5.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.87%
EBIT Next 3Y1.85%
EBIT Next 5Y-1.39%
FCF growth 1Y27.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.29%
OCF growth 3YN/A
OCF growth 5YN/A

ACTINIUM PHARMACEUTICALS INC / ATNM FAQ

What is the fundamental rating for ATNM stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATNM.


Can you provide the valuation status for ACTINIUM PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ACTINIUM PHARMACEUTICALS INC (ATNM). This can be considered as Overvalued.


Can you provide the profitability details for ACTINIUM PHARMACEUTICALS INC?

ACTINIUM PHARMACEUTICALS INC (ATNM) has a profitability rating of 0 / 10.


Can you provide the financial health for ATNM stock?

The financial health rating of ACTINIUM PHARMACEUTICALS INC (ATNM) is 4 / 10.


What is the expected EPS growth for ACTINIUM PHARMACEUTICALS INC (ATNM) stock?

The Earnings per Share (EPS) of ACTINIUM PHARMACEUTICALS INC (ATNM) is expected to grow by 13.26% in the next year.